Comparison of Clopidogrel and Ticagrelor on Microvascular Dysfunction in ST-Segment Elevation Myocardial Infarction

Comparison of Clopidogrel and Ticagrelor on Microvascular Dysfunction in Acute Coronary Syndrome Patients: The Index of MIcrocirculatory Resistance After PCI in STEMI Patients (TIME Study)

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02026219

Enrollment

Registered

2014-01-01

Start date

2013-10-31

Completion date

2014-12-31

Last updated

2015-10-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-ST Segment Elevation Myocardial Infarction, ST Segment Elevation Myocardial Infarction

Brief summary

Ticagrelor is a non-thienophyridine, direct P2Y12 blocker that is more potent than clopidogrel and is associated with less interindividual variability. In the PLATO trial, it was found to be superior to clopidogrel with respect to cardiovascular outcomes and total mortality without increasing the risk of bleedings. More potent and reversible receptor bindings are possible explanation for the superior outcomes. Beside the potent effect on inhibition of antiplatelet function, ticagrelor has previously been demonstrated to increase adenosine levels by inhibiting adenosine re-uptake in tissue level and can induce adenosine triphosphate (ATP) release from human red cells, which both stimulate vasodilation of in red blood cells.

Interventions

DRUGClopidogrel

Clopidogrel 600mg loading

DRUGTicagrelor

Ticagrelor 180mg loading

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Inclusion Criteria: * Males and Females * between the ages of 18 and 75 years * STEMI patients treated with percutaneous coronary intervention * Able to provide informed consent *

Exclusion criteria

* History of stroke or transient ischemic attack * Platelet count \< 100 000/μL * Known Bleeding Diathesis * Hematocrit \<30% or \>52% * Severe Liver Dysfunction * Renal Insufficiency (Creatinine Clearance \< 30ml/min) * Pregnant females * Cardiogenic shock or symptomatic hypotension or sitting SBP \< 95 mmHg

Design outcomes

Primary

Measure	Time frame
Index of microcirculatory resistance (IMR) measured after successful coronary intervention	IMR will be immediately assessed after successful PCI patients within 48hr from admission

Secondary

Measure	Time frame
wall motion score index on three month later TTE from index PCI	TTE will be assessed in all enrolled patients 3 month later from index PCI

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 20, 2026